David Bushnell

11.0k total citations · 1 hit paper
232 papers, 5.3k citations indexed

About

David Bushnell is a scholar working on Civil and Structural Engineering, Mechanics of Materials and Epidemiology. According to data from OpenAlex, David Bushnell has authored 232 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Civil and Structural Engineering, 70 papers in Mechanics of Materials and 47 papers in Epidemiology. Recurrent topics in David Bushnell's work include Composite Structure Analysis and Optimization (64 papers), Neuroendocrine Tumor Research Advances (42 papers) and Neuroblastoma Research and Treatments (39 papers). David Bushnell is often cited by papers focused on Composite Structure Analysis and Optimization (64 papers), Neuroendocrine Tumor Research Advances (42 papers) and Neuroblastoma Research and Treatments (39 papers). David Bushnell collaborates with scholars based in United States, United Kingdom and Canada. David Bushnell's co-authors include Yusuf Menda, Robert T. Jensen, David S. Klimstra, James C. Yao, Stanley J. Goldsmith, Martyn Caplin, Matthew H. Kulke, William D. Bushnell, Richard P. Baum and Daniel Kahn and has published in prestigious journals such as Nature, Journal of Clinical Oncology and Blood.

In The Last Decade

David Bushnell

217 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With ¹⁷⁷Lu-Dotatate in the Phase III NETTER-1 Trial

2018 272 citations Jonathan Strosberg, Edward M. Wolin et al. profile →

Peers

Countries citing papers authored by David Bushnell

Since Specialization

Citations

This map shows the geographic impact of David Bushnell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Bushnell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Bushnell more than expected).

Fields of papers citing papers by David Bushnell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Bushnell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Bushnell. The network helps show where David Bushnell may publish in the future.

Co-authorship network of co-authors of David Bushnell

This figure shows the co-authorship network connecting the top 25 collaborators of David Bushnell. A scholar is included among the top collaborators of David Bushnell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Bushnell. David Bushnell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Quantifying the rear side contribution in bifacial tandem-photovoltaic devices 2024 ·FreiDok plus (Universitätsbibliothek Freiburg) ·(unknown), Marc Steiner, S. Kasimir Reichmuth, (unknown), Gerald Siefer, S. E. Hooper, David Bushnell, Daniel Kirk, (unknown), Stefan W. Glunz	1
2	Peptide Receptor Radionuclide Therapy Is Effective for Clinical Control of Symptomatic Metastatic Insulinoma: A Long-Term Retrospective Analysis 2023 ·Journal of Nuclear Medicine ·(unknown), Martin T. Freitag, Martin Braun, Guillaume Nicolas, Andreas Bauman, David Bushnell, Emanuel Christ, Damian Wild	12
3	Potential for Increasing Uptake of Radiolabeled ⁶⁸ Ga-DOTATOC and ¹²³ I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor Vorinostat 2021 ·Cancer Biotherapy and Radiopharmaceuticals ·Janet H. Pollard, Yusuf Menda, K. D. Zamba, Mark T. Madsen, M. Sue O’Dorisio, Thomas M. O’Dorisio, David Bushnell	11
4	Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with ¹⁷⁷Lu-DOTATATE 2021 ·Journal of Nuclear Medicine ·Jonathan Strosberg, Rajaventhan Srirajaskanthan, Ghassan El‐Haddad, Edward M. Wolin, Beth Chasen, Matthew H. Kulke, David Bushnell, Martyn Caplin, Richard P. Baum, Andrew Hendifar, Kjell Öberg, Philippe Ruszniewski, Paola Santoro, Per Broberg, Oscar Leeuwenkamp, Eric P. Krenning, (unknown)	14
5	QOL Improvements in NETTER-1 Phase III Trial in Patients With Progressive Midgut Neuroendocrine Tumors 2018 ·Pancreas ·Jonathan Strosberg, Edward M. Wolin, Beth Chasen, (unknown), David Bushnell, Martyn Caplin, Richard P. Baum, Pamela L. Kunz, Timothy J. Hobday, (unknown), Kjell Öberg, Maribel Lopera Sierra, Philippe Ruszniewski, (unknown)	3
6	⁹⁰Y-DOTATOC Dosimetry–Based Personalized Peptide Receptor Radionuclide Therapy 2018 ·Journal of Nuclear Medicine ·Yusuf Menda, Mark T. Madsen, Thomas M. O’Dorisio, John J. Sunderland, G. Leonard Watkins, Joseph S. Dillon, Sarah L. Mott, Michael K. Schultz, Gideon Zamba, David Bushnell, M. Sue O’Dorisio	36
7	NETTER-1 Phase III Trial : Recent Findings on Quality of Life in Patients with Midgut Neuroendocrine Tumors 2017 ·Neuroendocrinology ·(unknown), Edward M. Wolin, Beth Chasen, M. Kulke, David Bushnell, (unknown), R. P. Baum, Pamela L. Kunz, Timothy J. Hobday, (unknown), Kjell Öberg, (unknown), D. J. Kwekkeboom, (unknown), E. P. Krenning	2
8	Localization of Unknown Primary Site with ⁶⁸Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor 2017 ·Journal of Nuclear Medicine ·Yusuf Menda, Thomas M. O’Dorisio, James R. Howe, Michael K. Schultz, Joseph S. Dillon, David Dick, G. Leonard Watkins, Timothy Ginader, David Bushnell, John J. Sunderland, Gideon Zamba, Michael M. Graham, M. Sue O’Dorisio	33
9	Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors 2016 ·Pancreas ·(unknown), Boris G. Naraev, (unknown), M. Bridget Zimmerman, David Bushnell, Thomas M. O’Dorisio, M. Sue O’Dorisio, Yusuf Menda, Jan Müller‐Brand, James R. Howe, Þorvarður R. Hálfdánarson	41
10	Feasibility and advantage of adding 131I-MIBG to 90Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors 2014 ·EJNMMI Research ·David Bushnell, Mark T. Madsen, (unknown), Yusuf Menda, (unknown), (unknown), M. Sue O’Dorisio	10
11	Standard Imaging Techniques for Neuroendocrine Tumors 2011 ·Endocrinology and Metabolism Clinics of North America ·David Bushnell, Richard P. Baum	49
12	Enhanced uptake of 99Tcm-MDP in skeletal metastases from prostate cancer following initiation of hormone treatment: Potential for increasing delivery of therapeutic agents 1999 ·Nuclear Medicine Communications ·David Bushnell, (unknown), Douglas Kahn, (unknown), Rachel Williams	5
13	Captopril-enhanced 99Tcm-MAG3 renal scintigraphy in subjects with suspected renovascular hypertension 1994 ·Nuclear Medicine Communications ·Daniel Kahn, Simona Ben‐Haim, David Bushnell, Mark T. Madsen, Peter T. Kirchner	10
14	Dosimetric Determination of 1-131 Activity in the Treatment of Recurrent, Nontoxic, Multinodular Goiter 1993 ·Clinical Nuclear Medicine ·Charles J. Bareis, David Bushnell, Gary E. Kaufman, Mario Sparagana	2
15	Comparison of IMP and HMPAO for SPECT Brain Imaging 1991 ·Journal of Nuclear Medicine Technology ·David Bushnell, (unknown), W. Earl Barnes	1
16	Recent developments in buckling of structures : presented at the Winter Annual Meeting of the American Society of Mechanical Engineers, San Francisco, California, December 10-15, 1989 1989 ·Hui Dai, (unknown), David Bushnell, (unknown)	1
17	Adenocarcinoma of the Prostate Presenting as a Single Focus of Radionuclide Accumulation in the Mandible on Bone and Gallium Images 1989 ·Clinical Nuclear Medicine ·(unknown), (unknown), Parvez Shirazi, David Bushnell	0
18	Scintigraphic evaluation of the urinary system in a case of severe renal trauma. 1984 ·PubMed ·David Bushnell, Robert E. Polcyn, David T. Uehling	0
19	Panel Optimization with Integrated Software (POIS). Volume 1: PANDA: Interactive program for preliminary minimum weight design 1981 ·David Bushnell	1
20	NONLINEAR ANALYSIS FOR AXISYMMETRIC ELASTIC STRESSES IN RING-STIFFENED, SEGMENTED SHELLS OF REVOLUTION 1968 ·Defense Technical Information Center (DTIC) ·David Bushnell	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact